View Post

New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors

In Clinical Trials by Barbara Jacoby

From: cancerresearch.org 2,250 clinical trials are evaluating PD-1/L1 immune checkpoint inhibitors, an increase of 748 trials over the past year 1,716 trials are assessing regimens that combine PD-1/L1 immune checkpoints with other cancer therapies 240 drug targets are being evaluated in the current landscape, 75 more targets compared to a year ago Over 380,000 patient volunteers are required to fill …

View Post

NCRI 2018: Using liquid biopsies to understand cancer treatment

In In The News by Barbara Jacoby

By: Francis Newman From: icr.ac.uk Testing for cancer cells and DNA in the bloodstream is showing huge promise as a way of monitoring cancers and how they are responding to treatment. At the 2018 NCRI conference in Glasgow, ICR researchers spoke about how these so-called liquid biopsies can guide clinical decisions for cancer patients. A liquid biopsy is a new …

View Post

New Clinical Research on Chimeric Antigen Receptor (CAR) T-Cell Therapy Presented at 60th American Society of Hematology Annual Meeting

In Clinical Trials by Barbara Jacoby

Source:    Yadira Galindo, Health Journalist The 60th American Society of Hematology (ASH) Annual Meeting, the largest international conference and exhibition in the field of hematology, is currently taking place at the San Diego Convention Center.  Dr. Peihua Lu, the Medical Executive President of the Hebei Yanda Lu Daopei Hospital, and Dr. Xian Zhang from the same institution were invited by …

View Post

The future of fighting cancer: Zapping tumors in less than a second

In In The News by Barbara Jacoby

Source: DOE/SLAC National Accelerator Laboratory From: sciencedaily.com New accelerator-based technology being developed by the Department of Energy’s SLAC National Accelerator Laboratory and Stanford University aims to reduce the side effects of cancer radiation therapy by shrinking its duration from minutes to under a second. Built into future compact medical devices, technology developed for high-energy physics could also help make radiation …

View Post

QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs

In Clinical Trials by Barbara Jacoby

Source: QIAGEN From: apnews.com Nov 30, 2018–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients. The partnership between QIAGEN and NeoGenomics, a leading provider of cancer-focused genetic testing services, will ensure Day-One patient access to …

View Post

Breast cancer: Tumor growth fueled by bone marrow cells

In In The News by Barbara Jacoby

By: Ana Sandoiu From: medicalnewstoday.com New research, published in the Journal of Experimental Medicine, reveals a novel mechanism that fuels tumor growth in breast cancer and may have a negative impact on a person’s outlook. However, the findings might also help scientists develop individually tailored treatments that target breast cancer tumors more precisely. Neta Erez, a senior lecturer in the …

View Post

“How Connie Got Her Rack Back”

In In The News by Barbara Jacoby

“How Connie Got Her Rack Back” shares the incredible journey of Connie Bramer; a young woman, mom, daughter sister and friend who experienced breast cancer. Connie gives laugh out loud humor to her adventure, along with poignant moments of self-discovery as she blogs her way to good health. From the first page of this book you are laughing out loud …

View Post

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

In Clinical Trials by Barbara Jacoby

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a novel, versatile, multi-functional platform- -Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favorable safety profile in early stage cervical cancer- -Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 …